Sydney, Australia 30 October 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that interim-CEO, Dr Colin Biggin, has moved to Managing Director and CEO of the Company, to lead Clarity through the next stages of clinical development and commercialisation.
Dr Biggin’s background in radiopharmaceutical development is extensive with over 15 years in the industry, including his experience at Algeta ASA (Algeta) where he worked in multiple roles from 2006 up to Algeta’s acquisition by Bayer for US$2.9 billion in 2014. Dr Biggin was among the first ten employees at Algeta and was responsible for providing scientific and project support across all departments, gaining broad expertise in the development and commercialisation of radiopharmaceuticals. He was significantly involved in the development and launch of Xofigo, Algeta’s lead radiopharmaceutical product targeting metastatic prostate cancer. Dr Biggin gained his PhD in Environmental Radiochemistry and a BSc in Environmental Biogeochemistry from the University of Glasgow.
After previously being with Clarity for 2 years, Dr Biggin moved to interim-CEO six months ago to replace former Managing Director and founding CEO Dr Matt Harris. As part of Dr Biggin’s move to Managing Director, Dr Matt Harris has resigned from the Board and will continue in his role as Clarity’s Chief Scientific Officer.
Dr Biggin commented on his appointment, “I am looking forward to continuing to steer Clarity through this important phase of clinical development towards commercialisation of our copper-based theranostic platform in my new role as Managing Director. During my time as acting-CEO at Clarity, we have progressed a number of important regulatory and clinical milestones across our pipeline. I am excited to lead the Clarity team forward through the development phase to our ultimate goal of better treating children and adults with cancer”.
Dr Matt Harris commented on the changes, “It is an exciting time for Clarity. Being able to attract high-calibre people to the Company is testament to the Company’s outstanding technology and market positioning. I have thoroughly enjoyed my role in helping Clarity get to where it is today from inception and I remain committed to the success of Clarity in my role as CSO and as a member of the senior executive team. It is great to see the Company move to this next stage of commercialisation and I look forward to supporting Colin and the rest of the team moving forward.”
Clarity’s Executive Chairman, Dr Alan Taylor commented, “The changes at the Board level are an important step for moving our focus from early stage to late stage clinical development and preparing the company for commercial success. With Dr Thomas Ramdahl and Dr Gillies O’Bryan-Tear, both formerly of Algeta, having joined the Board this year, as well as attracting a number of high-calibre executives to Clarity, we are now building a Board and management team with a unique mix of expertise and experience of successfully growing companies in the pharmaceutical industry.”
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
